Clinical Trials · NCT00911443
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- sigma-tau i.f.r. S.p.A.
- Enrollment
- 488
- Start date
- Jul 2002
- Locations
- 64 sites, 8 countries
- Primary endpoint
- Overall Tumor Response